top of page
Background.png

For Investors

BCAL Diagnostics (ASX: BDX) is commercialising a next-generation, patient-friendly blood test to enable more effective diagnosis of breast cancer.

The purpose of this webpage and subsequent document is to provide information to existing and prospective investors, and potential commercial partners, about the current status of BCAL’s research and development. It is not intended to promote the use or supply of any therapeutic goods.

Prospectus

BY DOWNLOADING, PRINTING OR VIEWING THE PROSPECTUS YOU ACKNOWLEDGE READING, AND AGREE TO, THE TERMS SET OUT BELOW

bottom of page